RxDoctor Payments Data

Tiny Adams

Psychiatric/Mental Health · Albuquerque, NMNPI 1669403218

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,503in general payments, 2019–2025

Across 286 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$909
  • Neurocrine Biosciences, Inc.$549
  • Teva Pharmaceuticals USA, Inc.$422
  • Otsuka America Pharmaceutical, Inc.$259
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,34497%
  • Education$1583%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,503 in reported general payments places this provider in the 95th percentile of 228 psychiatric/mental health providers in New Mexico.

See all psychiatric/mental health providers in New Mexico

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl37$57,518
Abilify MaintenaAripiprazole16$38,743
Aripiprazole35$2,823
Vilazodone Hcl16$1,500
Trazodone Hcl149$922
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine23$792
Paliperidone ErPaliperidone11$727
Quetiapine Fumarate73$679
Clonazepam70$645
Olanzapine39$537
Duloxetine Hcl36$531
Fluoxetine Hcl75$495
Mirtazapine51$493
Divalproex Sodium31$472
Hydroxyzine Pamoate29$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,038$57,51837 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$259$38,74316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 228 psychiatric/mental health providers in New Mexico.

Other psychiatric/mental health in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →